Arjun Pennathur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arjun Pennathur has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Alessandro Brunelli
Department of Thoracic Surgery, St. James's University Hospital, Leeds, United Kingdom
5 shared publicationsAndrea Wolf
Department of Thoracic Surgery, The Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, New York, NY
5 shared publicationsBetty Tong
Department of Thoracic Surgery, Duke University Hospital, Durham, NC
5 shared publicationsBilly W. Loo
Department of Radiation Oncology & Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
5 shared publicationsBrian Pettiford
Section of Cardiothoracic Surgery, Ochsner Health System, New Orleans, La
5 shared publicationsGaetano Rocco
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
5 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaeb9836
CASTOR1 functional inactivation drives KRAS -mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression
CASTOR1, a cytosolic arginine sensor and regulator of mTORC1 signaling, is identified here as a tumor suppressor in KRAS -driven non–small cell lung cancer (NSCLC). In a KRAS G12D mouse model, CASTOR1 deletion enhances tumor initiation and progression, accompanied by increased proliferation. Although CASTOR1 is rarely mutated or deleted in human cancers, its expression progressively declines during tumor progression and is associated with increased AKT activation and CASTOR1 phosphorylation, consistent with functional inactivation. Loss of CASTOR1 results in constitutive mTORC1 hyperactivation, impaired arginine-dependent regulation of mTORC1 signaling, elevated p-4EBP1 and p-S6 levels, increased AKT and ERK activation, genomic instability, and resistance to KRAS G12D inhibitors. Tumors and tumor-derived organoids deficient in CASTOR1 are resistant to KRAS inhibition, but this resistance can be overcome by cotargeting mTORC1 or dual PI3K/mTOR inhibition. These findings identify CASTOR1 as a critical link between nutrient sensing and oncogenic signaling and reveal its functional inactivation as an important mechanism contributing to KRAS -driven NSCLC progression and therapeutic resistance. The results further support rational combination therapies to overcome KRAS inhibitor resistance in CASTOR1-low NSCLC.
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaeb9836
Open AccessCASTOR1 functional inactivation drives KRAS -mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression
CASTOR1, a cytosolic arginine sensor and regulator of mTORC1 signaling, is identified here as a tumor suppressor in KRAS -driven non–small cell lung cancer (NSCLC). In a KRAS G12D mouse model, CASTOR1 deletion enhances tumor initiation and progression, accompanied by increased proliferation. Although CASTOR1 is rarely mutated or deleted in human cancers, its expression progressively declines during tumor progression and is associated with increased AKT activation and CASTOR1 phosphorylation, consistent with functional inactivation. Loss of CASTOR1 results in constitutive mTORC1 hyperactivation, impaired arginine-dependent regulation of mTORC1 signaling, elevated p-4EBP1 and p-S6 levels, increased AKT and ERK activation, genomic instability, and resistance to KRAS G12D inhibitors. Tumors and tumor-derived organoids deficient in CASTOR1 are resistant to KRAS inhibition, but this resistance can be overcome by cotargeting mTORC1 or dual PI3K/mTOR inhibition. These findings identify CASTOR1 as a critical link between nutrient sensing and oncogenic signaling and reveal its functional inactivation as an important mechanism contributing to KRAS -driven NSCLC progression and therapeutic resistance. The results further support rational combination therapies to overcome KRAS inhibitor resistance in CASTOR1-low NSCLC.
- 14 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 106-113
Systematic Review of the Comparative Studies of Image-Guided Thermal Ablation, Stereotactic Radiosurgery, and Sublobar Resection for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer
- 14 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 106-113
Systematic Review of the Comparative Studies of Image-Guided Thermal Ablation, Stereotactic Radiosurgery, and Sublobar Resection for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer
- 12 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 99-105
Systematic Review of Sublobar Resection for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer
- 12 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 99-105
Systematic Review of Sublobar Resection for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer
- 9 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 75-81
The Importance of Pulmonary Nodule Features in the Selection of Treatment for the High-Risk Patient with Stage I Non-Small Cell Lung Cancer
- 9 December 2024
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 37 (1) , 75-81
The Importance of Pulmonary Nodule Features in the Selection of Treatment for the High-Risk Patient with Stage I Non-Small Cell Lung Cancer
- 29 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (87) , eadf6717
Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells
Human regulatory T cells (Tregs) are crucial regulators of tissue repair, autoimmune diseases, and cancer. However, it is challenging to inhibit the suppressive function of Tregsfor cancer therapy without affecting immune homeostasis. Identifying pathways that may distinguish tumor-restricted Tregsis important, yet the transcriptional programs that control intratumoral Treggene expression, and that are distinct from Tregsin healthy tissues, remain largely unknown. We profiled single-cell transcriptomes of CD4+T cells in tumors and peripheral blood from patients with head and neck squamous cell carcinomas (HNSCC) and those in nontumor tonsil tissues and peripheral blood from healthy donors. We identified a subpopulation of activated Tregsexpressing multiple tumor necrosis factor receptor (TNFR) genes (TNFR+Tregs) that is highly enriched in the tumor microenvironment (TME) compared with nontumor tissue and the periphery. TNFR+Tregsare associated with worse prognosis in HNSCC and across multiple solid tumor types. Mechanistically, the transcription factor BATF is a central component of a gene regulatory network that governs key aspects of TNFR+Tregs. CRISPR-Cas9–mediatedBATFknockout in human activated Tregsin conjunction with bulk RNA sequencing, immunophenotyping, and in vitro functional assays corroborated the central role of BATF in limiting excessive activation and promoting the survival of human activated Tregs. Last, we identified a suite of surface molecules reflective of the BATF-driven transcriptional network on intratumoral Tregsin patients with HNSCC. These findings uncover a primary transcriptional regulator of highly suppressive intratumoral Tregs, highlighting potential opportunities for therapeutic intervention in cancer without affecting immune homeostasis.
- 29 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (87) , eadf6717
Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells
Human regulatory T cells (Tregs) are crucial regulators of tissue repair, autoimmune diseases, and cancer. However, it is challenging to inhibit the suppressive function of Tregsfor cancer therapy without affecting immune homeostasis. Identifying pathways that may distinguish tumor-restricted Tregsis important, yet the transcriptional programs that control intratumoral Treggene expression, and that are distinct from Tregsin healthy tissues, remain largely unknown. We profiled single-cell transcriptomes of CD4+T cells in tumors and peripheral blood from patients with head and neck squamous cell carcinomas (HNSCC) and those in nontumor tonsil tissues and peripheral blood from healthy donors. We identified a subpopulation of activated Tregsexpressing multiple tumor necrosis factor receptor (TNFR) genes (TNFR+Tregs) that is highly enriched in the tumor microenvironment (TME) compared with nontumor tissue and the periphery. TNFR+Tregsare associated with worse prognosis in HNSCC and across multiple solid tumor types. Mechanistically, the transcription factor BATF is a central component of a gene regulatory network that governs key aspects of TNFR+Tregs. CRISPR-Cas9–mediatedBATFknockout in human activated Tregsin conjunction with bulk RNA sequencing, immunophenotyping, and in vitro functional assays corroborated the central role of BATF in limiting excessive activation and promoting the survival of human activated Tregs. Last, we identified a suite of surface molecules reflective of the BATF-driven transcriptional network on intratumoral Tregsin patients with HNSCC. These findings uncover a primary transcriptional regulator of highly suppressive intratumoral Tregs, highlighting potential opportunities for therapeutic intervention in cancer without affecting immune homeostasis.
- 8 December 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (623) , eabf8495
Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer
Persistent T cell receptor stimulation drives neuropilin-1 on intratumoral regulatory T cells, which is associated with poor clinical outcome.
- 8 December 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (623) , eabf8495
Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer
Persistent T cell receptor stimulation drives neuropilin-1 on intratumoral regulatory T cells, which is associated with poor clinical outcome.
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 160
Converting borderline-resectable, locally-advanced esophageal carcinoma to resectability with neoadjuvant chemoradiotherapy.
160 Background: Treatment of T3-4/N+ esophageal cancer is challenging. Outcomes are suboptimal and patterns of care are not well defined for borderline-resectable esophageal cancer (BREC). We present our institutional experience using preoperative chemoradiotherapy (CRT) in the management of BREC. Methods: We identified 67 patients with T3-4/N+ BREC who were treated with concurrent CRT between 2009 and 2014. Survival was calculated with Kaplan-Meier curves and cohort comparisons were made with log-rank test and Cox regression. Results: We treated 67 patients (81% males, median age 61 years, and KPS of 80), primarily with T3N2 disease. Median follow-up was 16 months. The most common CRT regimen was 58.8Gy in 28 fractions with carboplatin and paclitaxel. Median survival was 16.5 months. Forty two (62.7%) patients underwent minimally invasive Ivor-Lewis esophagectomy within 100 days of CRT. Resected patients had a median survival of 30.6 vs. 6.4 months without surgery (p<.001). Pathologic complete response and pN0 was 30.0% and 59.5%, respectively. Acute grade 3+ toxicity was seen in 34.3% and late grade 3+ toxicity in 49.3%. Three patients (4.5%) died during CRT or before surgery. Predictors of overall survival (OS) on univariate analysis included age, KPS, male gender, absence of radiographic progression and surgical resection (all p<.05). Surgery remained significant on multivariate analysis (HR 0.215 [95%CI .114-.408, p<.001]). For resected patients, survival was predicted by positive margins, pathologic N stage, and number of positive nodes (all p<.05). The only predictor of OS on multivariate analysis was pathologic N stage, with actuarial 1- and 2-year OS for pN0 vs. pN+ of 96.2%/73.1% vs 53.3%/40.0% (p=.001). pN+ patients receiving adjuvant chemotherapy (53.3%) had improved survival of 26.7 vs 8.3 months without (p=.023). Conclusions: Preoperative CRT enabled a significant proportion of patients with BREC to proceed with a potentially curative resection. Further investigation with careful patient selection is warranted in incorporating a trimodality strategy to optimize outcomes and better define a treatment algorithm for this complex cohort of patients.
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 160
Converting borderline-resectable, locally-advanced esophageal carcinoma to resectability with neoadjuvant chemoradiotherapy.
160 Background: Treatment of T3-4/N+ esophageal cancer is challenging. Outcomes are suboptimal and patterns of care are not well defined for borderline-resectable esophageal cancer (BREC). We present our institutional experience using preoperative chemoradiotherapy (CRT) in the management of BREC. Methods: We identified 67 patients with T3-4/N+ BREC who were treated with concurrent CRT between 2009 and 2014. Survival was calculated with Kaplan-Meier curves and cohort comparisons were made with log-rank test and Cox regression. Results: We treated 67 patients (81% males, median age 61 years, and KPS of 80), primarily with T3N2 disease. Median follow-up was 16 months. The most common CRT regimen was 58.8Gy in 28 fractions with carboplatin and paclitaxel. Median survival was 16.5 months. Forty two (62.7%) patients underwent minimally invasive Ivor-Lewis esophagectomy within 100 days of CRT. Resected patients had a median survival of 30.6 vs. 6.4 months without surgery (p<.001). Pathologic complete response and pN0 was 30.0% and 59.5%, respectively. Acute grade 3+ toxicity was seen in 34.3% and late grade 3+ toxicity in 49.3%. Three patients (4.5%) died during CRT or before surgery. Predictors of overall survival (OS) on univariate analysis included age, KPS, male gender, absence of radiographic progression and surgical resection (all p<.05). Surgery remained significant on multivariate analysis (HR 0.215 [95%CI .114-.408, p<.001]). For resected patients, survival was predicted by positive margins, pathologic N stage, and number of positive nodes (all p<.05). The only predictor of OS on multivariate analysis was pathologic N stage, with actuarial 1- and 2-year OS for pN0 vs. pN+ of 96.2%/73.1% vs 53.3%/40.0% (p=.001). pN+ patients receiving adjuvant chemotherapy (53.3%) had improved survival of 26.7 vs 8.3 months without (p=.023). Conclusions: Preoperative CRT enabled a significant proportion of patients with BREC to proceed with a potentially curative resection. Further investigation with careful patient selection is warranted in incorporating a trimodality strategy to optimize outcomes and better define a treatment algorithm for this complex cohort of patients.
- 20 May 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (15_suppl) , 7515
Clinical impact of age on outcomes following anatomic lung resection for stage I non-small cell lung cancer
7515 Background: There is an increasing body of evidence that anatomic segmentectomy may represent an equivalent approach compared to lobectomy in the management of stage I NSCLC. Comorbidities associated with age may result in improved survival with sublobar resection for stage I cancer in the elderly. We report our single institution experience with segmentectomy vs. lobectomy for stage I non-small cell lung cancer stratified by age. Methods: A total of 232 consecutive anatomic segmentectomies were performed for stage IA (n=137) or IB (n=95) NSCLC from 2002–2007. Lobectomy was performed in 594 patients for stage IA (n=297) and IB (n=295) during the same period. Results of segmental resection were compared with lobectomy, stratified by the following age groups: 80 years old. Conclusions: Anatomic segmentectomy can be performed with similar morbidity, mortality, recurrence, and survival compared to lobectomy in stage I lung cancer. This approach may be particularly advantageous in the elderly age group, achieving comparable oncologic outcomes with less mortality and improved overall survival. No significant financial relationships to disclose.
- 20 May 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (15_suppl) , 7515
Clinical impact of age on outcomes following anatomic lung resection for stage I non-small cell lung cancer
7515 Background: There is an increasing body of evidence that anatomic segmentectomy may represent an equivalent approach compared to lobectomy in the management of stage I NSCLC. Comorbidities associated with age may result in improved survival with sublobar resection for stage I cancer in the elderly. We report our single institution experience with segmentectomy vs. lobectomy for stage I non-small cell lung cancer stratified by age. Methods: A total of 232 consecutive anatomic segmentectomies were performed for stage IA (n=137) or IB (n=95) NSCLC from 2002–2007. Lobectomy was performed in 594 patients for stage IA (n=297) and IB (n=295) during the same period. Results of segmental resection were compared with lobectomy, stratified by the following age groups: 80 years old. Conclusions: Anatomic segmentectomy can be performed with similar morbidity, mortality, recurrence, and survival compared to lobectomy in stage I lung cancer. This approach may be particularly advantageous in the elderly age group, achieving comparable oncologic outcomes with less mortality and improved overall survival. No significant financial relationships to disclose.